Explore daily insights on
BioCardia volume jumps 463x on FDA heart therapy support
- BioCardia shares surged under massive volume after receiving positive regulatory feedback from the FDA for its heart failure cell therapy.
- Trading volume spiked to 150,347,798 shares, representing a 463-fold increase over its 20-day average of 324,426 shares.
- This regulatory milestone provides a clear path toward premarket approval, significantly boosting investor confidence in the clinical study.
Supporting datasets
Supporting queries
To surface this insight, Baselight ran 3 queries across its structured data. Each one is reproducible — open it, read the SQL, and rerun it yourself.
Conclusion
On June 5, 2026, trading volume for BCDA spiked to 150,347,798 shares, representing a 463x increase over its 20-day average of 324,426 shares. The stock closed up 12.1% at $1.03, after touching an intraday high of $1.80 (a 95.8% gain from the previous close of $0.919).